Abbott received European regulatory approval to introduce its FreeStyle Optium Neo Blood Glucose and Ketone Monitoring System to the EU market. The device uses already available FreeStyle Optium blood glucose and ketone test strips, and provides a new, friendlier user interface based on icons.
The Optium Neo tracks glucose readings and logs insulin injections, providing users with historic charts that can be shared with physicians to adjust therapy, diet, and other factors that can influence the symptoms of diabetes.
Features according to Abbott:
- A high contrast, icon-driven display designed for ease-of-use
- Small, sleek meter design
- Blood glucose trend indicators, which visually notify patients when they are experiencing hypo- or hyperglycemic trends (low or high blood glucose levels)
- An insulin dose feature, which allows healthcare professionals to program a patient’s insulin plan into the meter. Beginning from the physician’s recommendation in the dose guide, the meter is designed to allow patients to log actual insulin doses by tapping the arrows up or down. This feature is designed to enable patients and their healthcare professionals to review logged insulin doses along with glucose results.
Press release: Abbott Receives CE Mark for FreeStyle Optium Neo Blood Glucose and Ketone Monitoring System™…
